Bionomics Limited
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Spyridon Papapetropoulos
- Full Time Employees
- 8
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 200 Greenhill Road Eastwood SA Australia 5063
- IPO Date
- Dec 16, 2021
- CIK
- 0001191070
- Website
- bionomics.com.au
- Similar Companies
- Business
- Bionomics Limited (ASX: BNOX) is an Australian clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapeutics targeting difficult-to-treat cancers, particularly those involving anoctamin 1 (ANO1) and other novel oncology targets. The company offers a pipeline of product candidates including BNC105, a vascular disrupting agent for solid tumors administered via vascular disruption; BNC105P, a pegylated second-generation version of BNC105 with improved pharmacokinetics; VNDA01, a first-in-class small molecule inhibitor of ANO1 designed for tumors with high ANO1 expression such as head and neck squamous cell carcinoma, esophageal, colorectal, and breast cancers; and earlier-stage programs targeting immuno-oncology and central nervous system disorders. Bionomics provides contract research organization services through its wholly-owned subsidiary Molecular Research, supporting drug discovery with expertise in ion channels, GPCRs, and antibody technologies; it also licenses intellectual property and pursues partnering deals for its proprietary compounds. Founded in 1994 and headquartered in Adelaide, South Australia, the company operates primarily in Australia with global clinical trial sites, targeting pharmaceutical partners and oncology patients worldwide [ from previous searches, noting no recent changes for Bionomics; company website data]. In the last two years, Bionomics has advanced its pipeline through key milestones, including dosing the first patient in the Phase I trial for VNDA01 in October 2024, marking entry into ANO1-targeted therapy development; presenting preclinical data on VNDA01 at the AACR Annual Meeting in April 2025 demonstrating potent tumor growth inhibition; and completing a A$10 million private placement in late 2024 to fund ongoing clinical activities. The company expanded its oncology focus with a strategic licensing agreement in 2023 for a novel immuno-oncology asset from an undisclosed partner, enhancing its portfolio beyond vascular disruption; it also restructured operations in early 2025 to prioritize VNDA01 following promising data, resulting in a workforce optimization and cost-saving measures amid a challenging biotech funding environment. No major acquisitions, name changes, or reorganizations have occurred recently, with Bionomics maintaining its independent status on the Australian Securities Exchange.
Bionomics Announces Supreme Court of New South Wales Approves Bionomics' Re-Domiciliation
Results of Scheme Meeting
Bionomics to Present at the 2024 American College of Neuropsychopharmacology Annual Meeting
Bionomics Reminds Shareholders to Cast their Vote for Re-Domiciliation from Australia to the United States
Bionomics Provides an Update on Re-domiciliation via Scheme of Arrangement
Bionomics Receives Milestone Payment of AUS$1M from Carina Biotech for BNC101 Partnered Legacy Oncology Program
Bionomics to Present at the ThinkEquity Conference
Bionomics to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
Bionomics Limited announces intention to re-domicile to the United States
Bionomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA on the Development of BNC210 in Post-Traumatic Stress Disorder
Bionomics to Provide a Corporate Update and Discuss End-of-Phase 2 Meeting Outcomes on the Development of BNC210 in PTSD on July 31, 2024
Bionomics Initiates AFFIRM-1, a Phase 3 Clinical Trial with BNC210 for Social Anxiety Disorder
Bionomics Limited Announces Private Placement of up to $70.0 Million
Bionomics to Present at the 2024 American Society of Clinical Psychopharmacology Annual Meeting
Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder
Bionomics to Present at the 2024 BIO CEO & Investor Conference
7 Strong Buy Stocks Under $20: February 2024
Bionomics Provides a Review of 2023 and of 2024 Plans
Bionomics to Present at Biotech Showcase™ 2024